汪俊 博士
上海美迪西生物醫(yī)藥股份有限公司生物部副總裁

汪俊博士畢業(yè)于上海復(fù)旦大學(xué)，在日本神戶大學(xué)獲分子生物學(xué)和生物化學(xué)博士學(xué)位，在美國(guó)達(dá)拉斯德州大學(xué)西南醫(yī)學(xué)中心藥理學(xué)院完成了博士后研究。汪博士在美國(guó)德州大學(xué)西南醫(yī)學(xué)中心和華盛頓大學(xué)擔(dān)任了5年助教授；在默沙東公司（Merck）工作了9年，擔(dān)任課題總負(fù)責(zé)人；在Nature、Science等權(quán)威科學(xué)雜志上發(fā)表過(guò)多篇論文和專利，目前受聘于四個(gè)國(guó)際期刊的編委。作為新抗菌素--平板霉素和平板素的發(fā)現(xiàn)人，汪博士曾受邀英國(guó)劍橋大學(xué)和皇家化學(xué)會(huì)等多學(xué)府及科研機(jī)構(gòu)進(jìn)行學(xué)術(shù)演講。2010年汪俊博士加入美迪西，擔(dān)任生物研發(fā)部的副總裁。

牛俊奇 博士
吉林大學(xué)第一醫(yī)院肝病中心主任

主任醫(yī)師，教授，醫(yī)學(xué)博士,博士生導(dǎo)師，國(guó)務(wù)院特殊津貼專家。吉林大學(xué)轉(zhuǎn)化醫(yī)學(xué)研究院副院長(zhǎng), 吉林省肝病研究所所長(zhǎng)，吉林大學(xué)第一醫(yī)院肝膽胰內(nèi)科主任，吉林大學(xué)第一醫(yī)院臨床藥理機(jī)構(gòu)主任，吉林大學(xué)第一醫(yī)院感染性疾病診治中心主任，《臨床肝膽病雜志》主編，中國(guó)科學(xué)院上海巴斯德研究所和北華大學(xué)特聘教授，吉林省肝臟病學(xué)會(huì)委員會(huì)主任委員，吉林省傳染病學(xué)會(huì)名譽(yù)主任委員，亞洲及太平洋地區(qū)肝病學(xué)會(huì)會(huì)員，歐洲肝病學(xué)會(huì)會(huì)員，美國(guó)肝病學(xué)會(huì)會(huì)員。并擔(dān)任國(guó)內(nèi)外數(shù)十家雜志的編委委員，近年來(lái)在Hepatology，J Gastroenterol. Antiviral Res.  J Med Virol.等發(fā)表SCI檢索的論文四十多篇。最高影響因子11.665。先后承擔(dān)了“十一五”、“十二五”國(guó)家科技重大專項(xiàng)、863、973、國(guó)家自然科學(xué)基金等多項(xiàng)科研項(xiàng)目。擅長(zhǎng)病毒性肝炎,以及其他各類肝病、消化疾病的診斷及治療。獲衛(wèi)生部有突出貢獻(xiàn)中青年專家、吉林省資深高級(jí)專家、中華醫(yī)學(xué)科技二等獎(jiǎng)、吉林大學(xué)白求恩十大名醫(yī)等榮譽(yù)稱號(hào)。

Qun (Max) Dang, Ph.D.
Principal Scientist, Exploratory Chemistry
Merck Research Laboratories

Qun (Max) Dang obtained his B.S. degree in chemistry in 1985 from Jilin University and Ph.D. in chemistry from Purdue University in 1992 (under a CGP scholarship).  Max joined Gensia pharmaceuticals (later became Metabasis) in 1992 and worked until 2009 with his last position as director of medicinal chemistry. In 2009, Max joined the External Basic Research department of Merck Rahway site as a Senior Investigator; from 2011 to 2013, he was a Director of External Medicinal Chemistry based in Shanghai and currently he is a Principal Scientist of Exploratory Chemistry department at the Kenilworth site.

During his time at Metabasis, Max managed multiple drug discovery projects primarily in metabolic disease areas such as diabetes and dyslipidemia (such as FBPase inhibitors, glucagon antagonists, glucokinase activators, and AMPK activators). He also conducted researches in liver related disease such as hepatitis B, hepatitis C, liver cancer, liver fibrosis. Max's work at Metabasis led to two NCEs advancing to phase IIb clinical trials as potential treatment of type 2 diabetes.

Since joining Merck in 2009, Max managed several integrated drug discovery projects carried out at various CROs in the areas of infectious disease and endocrine. His research interests include medicinal chemistry via rational drug design, heterocyclic chemistry, prodrugs, and nucleoside chemistry. Dr. Dang has authored or co-authored 84 publications in peer-reviewed journals, 2 book chapters, and 50 granted patents and applications.